I-Mab (IMAB) Set to Announce Earnings on Thursday

I-Mab (NASDAQ:IMAB) will be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

I-Mab (NASDAQ:IMAB) last posted its earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

I-Mab Price Performance

IMAB stock opened at $1.10 on Tuesday. I-Mab has a fifty-two week low of $0.99 and a fifty-two week high of $2.54. The business’s 50-day moving average is $1.19 and its two-hundred day moving average is $1.43.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of I-Mab in a research note on Tuesday, September 17th.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.